Home  /  Resource Library  /  Glofitamab results in cost savings versus epcoritamab in relapsed/refractory diffuse large B-cell lymphoma: a total cost of care analysis

Glofitamab results in cost savings versus epcoritamab in relapsed/refractory diffuse large B-cell lymphoma: a total cost of care analysis

Cost-effectiveness analysis of glofitamab versus epcoritamab for treatment of relapsed DLBCL.